Logo image of CMND

CLEARMIND MEDICINE INC (CMND) Stock News

NASDAQ:CMND - Nasdaq - CA1850534027 - Common Stock - Currency: USD

1.0092  -0.01 (-1.06%)

After market: 1.03 +0.02 (+2.06%)

CMND Latest News, Press Relases and Analysis

News Image
12 days ago - Chartmill

Which stocks have an unusual volume on Monday?

Let's have a look at what is happening on the US markets on Monday. Below you can find the stocks with an unusual volume in today's session.

Mentions: AREC SPRB YGMZ MSGM ...

News Image
8 days ago - Yahoo Finance

Why Compass Pathways Stock Was a Double-Digit Winner This Week

Such a dynamic was in evidence with U.K.-based Compass Pathways (NASDAQ: CMPS) this week. On news about a step completed in a clinical trial, the company's shares rose by 13% over the period, according to data compiled by S&P Global Market Intelligence. Compass Pathways, which focuses on psilocybin -- the psychoactive compound found in "magic" mushrooms -- announced Tuesday that it had completed dosing in a late-stage clinical trial.

Mentions: CMPS APPF ET KMI ...

News Image
8 days ago - Clearmind Medicine Inc.

Clearmind Medicine Files International Patent Application for Novel Treatment of Anorexia, Bulimia and other Eating Disorders

Vancouver, Canada, April 25, 2025 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the

News Image
10 days ago - Clearmind Medicine Inc.

Clearmind Medicine Completes the Initiation of its Alcohol Use Disorder Phase I/IIa Clinical Trial at all Current Clinical Sites

The Company is now preparing for the enrollment of the first patient to receive Clearmind’s innovative treatment as part of the trial Vancouver, Canada,...

News Image
12 days ago - Clearmind Medicine Inc.

Clearmind Medicine to Host Live Webinar “Gazing Through the Crystal Ball” Featuring Leading Psychedelic Experts

Vancouver, Canada, April 21, 2025 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the

News Image
16 days ago - Clearmind Medicine Inc.

Clearmind Medicine Receives Notice of Allowance for United States Patent Covering Binge Behavior

Vancouver, Canada, April 17, 2025 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the

News Image
17 days ago - Clearmind Medicine Inc.

Clearmind Medicine Launches First U.S. Clinical Site for its FDA-Approved Clinical Trial to Combat Alcoholism

Vancouver, Canada, April 16, 2025 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the

News Image
23 days ago - Clearmind Medicine Inc.

Clearmind Medicine Announces First U.S. Clinical Site Initiation for CMND-100 Clinical Trial in Patients with Alcohol Use Disorder

Vancouver, Canada, April 10, 2025 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the

News Image
25 days ago - Clearmind Medicine Inc.

Clearmind Medicine Announces the Publication of International Patent Application for Next-Gen Psychedelic Compounds to Treat Mental Health Disorders

Vancouver, Canada, April 08, 2025 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the

News Image
a month ago - Clearmind Medicine Inc.

Clearmind Launches its EDC System to Support its Phase I/II Clinical Trial of its MEAI-Based Treatment

The clinical trial is designed to evaluate the safety, tolerability and efficacy of Clearmind’s innovative, psychedelic-derived, MEAI-based compound in...

News Image
a month ago - Clearmind Medicine Inc.

Clearmind Medicine’s FDA-Approved Clinical Trial for CMND-100 Moves Forward as Drug Arrives in the U.S., Advancing Toward Key Milestones

Vancouver, Canada, March 21, 2025 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the

News Image
2 months ago - Clearmind Medicine Inc.

Clearmind to Evaluate Intranasal Delivery of Its Psychedelic Drug Combination

Aiming to improve bioavailability and optimize the therapeutic effect of Clearmind’s psychedelic-based treatments Vancouver, Canada, March 19, 2025 ...

News Image
2 months ago - Clearmind Medicine Inc.

Clearmind Medicine Announces Initiation of First in Human Clinical Trial with CMND-100 in Alcohol Use Disorder Patients

Study represents the first clinical application of CMND-100, the Company’s proprietary drug platform Vancouver, Canada, March 18, 2025 (GLOBE NEWSWIRE)...

News Image
2 months ago - Benzinga

SciSparc Shares Are Soaring Monday: What's Going On?

SciSparc Ltd (NASDAQ:SPRC) shares are ripping higher Monday after the company announced that its collaboration with Clearmind Medicine Inc (NASDAQ:CMND) led to a patent application for psychedelic therapy targeting cocaine addiction.

Mentions: SPRC

News Image
2 months ago - Clearmind Medicine Inc.

Clearmind Medicine Announces Publication of Patent for Cocaine Addiction Psychedelic Combination Treatment in South Korea

Vancouver, Canada, March 10, 2025 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the

News Image
3 months ago - Clearmind Medicine Inc.

Clearmind Medicine Announces Publication of Patent for Binge Behavior Psychedelic Combination Treatment in Mexico

Vancouver, Canada, Feb. 04, 2025 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the

News Image
4 months ago - Clearmind Medicine Inc.

Clearmind Medicine Announces Shareholders Meeting Results

News Image
4 months ago - Clearmind Medicine Inc.

Clearmind Medicine Announces Shareholders Meeting Results

Vancouver, Canada, Jan. 07, 2025 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the “Company”), a...

News Image
4 months ago - Yahoo Finance

Why Is Psychedelic-SciSparc Stock Trading Higher On Monday?

On Monday, SciSparc Ltd (NASDAQ:SPRC) stock is trading higher with a session volume of 30.86 million compared to an average volume of 7.73 million as per data from Benzinga Pro. SciSparc announced, as part of its ongoing collaboration with Clearmind Medicine Inc. (NASDAQ:CMND), the publication of a European patent application submitted by Clearmind under the European Patent Office for combination therapy of MEAI and N-Acylethanolamines for binge behavior, including alcohol consumption, eating, t

Mentions: SPRC

News Image
4 months ago - Benzinga

Why Is Psychedelic-SciSparc Stock Trading Higher On Monday?

SciSparc teams up with Clearmind Medicine on innovative therapies for binge behaviors and secures FDA approval for a Tourette Syndrome Phase 2b trial.

Mentions: SPRC

News Image
4 months ago - Clearmind Medicine Inc.

Clearmind Medicine Announces the Publication of European Patent Application for Binge Behavior Psychedelic Combination Treatment

Vancouver, Canada, Jan. 06, 2025 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the